Ryan H. Wong serves as Executive Vice President and Chief Financial Officer at Sarepta Therapeutics Inc., a precision genetic medicine company dedicated to developing therapies for rare diseases, particularly Duchenne muscular dystrophy. He joined Sarepta in September 2021, bringing over two decades of experience in finance leadership within the biotechnology and pharmaceutical sectors. In his role, Wong oversees all financial operations, including accounting, financial planning and analysis, tax, treasury, investor relations, and corporate development, playing a pivotal role in supporting the company's pipeline expansion and commercial growth amid complex regulatory and market dynamics. Prior to Sarepta, Wong was Chief Financial Officer at Turning Point Therapeutics from 2019 to 2021, where he led the company's initial public offering on Nasdaq, raising over $460 million, and navigated its subsequent acquisition by Bristol Myers Squibb for $4.1 billion. He previously served as CFO at Relypsa Inc. from 2016 to 2018, guiding the company through its commercial launch of Veltassa and its $1.3 billion acquisition by Galenica (a Novartis division). Earlier in his career, Wong held senior finance positions at Onyx Pharmaceuticals (acquired by Amgen) and Deloitte, honing his expertise in strategic financial management, mergers and acquisitions, and capital markets. Wong's achievements include driving financial strategies that fueled multiple successful biotech exits and IPOs, earning him recognition for operational excellence in high-growth environments. A Certified Public Accountant, he holds an MBA from the University of Southern California and a BS in Electrical Engineering and Computer Science from the University of California, Berkeley. Under his leadership at Sarepta, the company has advanced key approvals and partnerships, solidifying its position as a leader in RNA-targeted therapeutics.